Akari Therapeutics plc has established a strategic partnership with Wuxi XDC Cayman Inc. to accelerate the development of Akari’s novel PH1 payload. Akari’s lead program, AKTX-101, is initially targeting metastatic urothelial cancer.
Major contract research development and manufacturing organizations (CDMO) out of Asia are announcing plans to ramp up production and antibody-drug conjugate (ADC) capabilities worldwide.
Major contract research development and manufacturing organizations (CDMO) out of Asia are announcing plans to ramp up production and antibody-drug conjugate (ADC) capabilities worldwide.
